[{"from": "human", "value": "Provide a brief overview of this molecule. [C][N][C][=Branch1][C][=O][C][=C][C][=C][C][=C][Ring1][=Branch1][N][C][=N][C][=Branch1][#Branch1][=N][C][=C][Ring1][=Branch1][Cl][N][C][=C][Branch2][Ring1][P][C][=C][Branch2][Ring1][#Branch1][C][C@H1][Branch1][=Branch1][C][C][C][Ring1][#Branch1][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][C][O][C][=C][Ring2][Ring1][Ring2][O][C]"}, {"from": "gpt", "value": "The molecule is an orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon administration, ALK-FAK inhibitor CEP-37440 selectively binds to and inhibits ALK kinase and FAK kinase. The inhibition leads to disruption of ALK- and FAK-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK- and FAK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; its dysregulation and gene rearrangements are associated with a variety of tumors. The cytoplasmic tyrosine kinase FAK, a signal transducer for integrins, is upregulated and constitutively activated in various tumor types; it plays a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis."}]